Minor salivary gland stem cells: a comparative study of the biological properties under clinical-grade culture conditions.
Clinical-grade expansion
Good manufacturing practice compliant cell preparation
Minor salivary gland stem cells (mSG-SCs)
Prolonged culture
“Stemness” properties
Journal
Cell and tissue research
ISSN: 1432-0878
Titre abrégé: Cell Tissue Res
Pays: Germany
ID NLM: 0417625
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
27
04
2022
accepted:
12
05
2023
medline:
8
8
2023
pubmed:
30
5
2023
entrez:
30
5
2023
Statut:
ppublish
Résumé
Development of clinical-grade, cell preparations is central to cGMP (good manufacturing practice compliant) conditions. This study aimed to investigate the potential of two serum/xeno-free, cGMP (StemPro, StemMacs) culture media to maintain "stemness" of human minor salivary gland stem cell (mSG-SC) cultures compared to a complete culture medium (CCM). Overall, StemMacs resulted in higher proliferation rates after p.6 compared to the conventional serum-based medium, while StemPro showed substantial delays in cell proliferation after p.9. The mSG-SCs cultures exhibited two distinct cell populations at early passages a mesenchymal subpopulation and an epithelial-like subpopulation. Expression of several markers (CD146, STRO-1, SSEA-4, CD105, CD106, CD34, K 7/8, K14, K18) variably decreased with prolonged passaging (all three media). The percentage of SA-β-gal positive cells was initially higher for StemMacs compared to StemPro/CCM and increased with prolonged passaging in all cases. The telomere fragment length decreased with prolonged passaging in all three media but more pronouncedly for the CCM. Expansion under serum-free conditions caused pronounced upregulation of ALP and BMP-2, with parallel complete elimination of the baseline expressions of LPL (all three media) and ACAN (serum-free media), therefore, showing a preferential shift of the mSG-SCs towards osteogenic phenotypes. Finally, several markers (Nanog, SOX-2, PDX-1, OTX2, GSC, HCG) decreased with prolonged culture, indicating successive loss of "stemness". Based on the findings, it seems that StemPro preserve stemness of the mSG-SCs after prolonged culture. Nevertheless, there is still a vacant role for the ideal development of clinical-grade culture conditions.
Identifiants
pubmed: 37249709
doi: 10.1007/s00441-023-03789-z
pii: 10.1007/s00441-023-03789-z
pmc: PMC10406694
doi:
Substances chimiques
Biomarkers
0
Culture Media
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
321-342Subventions
Organisme : Hellenic Foundation for Research and Innovation (H.F.R.I.)
ID : 3549
Informations de copyright
© 2023. The Author(s).
Références
Stem Cells. 2019 Sep;37(9):1144-1150
pubmed: 31175700
Dev Cell. 2015 Apr 20;33(2):231-7
pubmed: 25843887
Nucleic Acids Res. 2014 Feb;42(3):e21
pubmed: 24366880
Cytotherapy. 2017 Feb;19(2):155-169
pubmed: 28017599
Nat Rev Mol Cell Biol. 2007 Sep;8(9):729-40
pubmed: 17667954
Genesis. 2018 May;56(5):e23211
pubmed: 29663717
Stem Cells. 2005 Oct;23(9):1357-66
pubmed: 16081661
Stem Cells. 2006 Feb;24(2):462-71
pubmed: 16109759
J Dent Res. 2014 Jan;93(1):55-61
pubmed: 24170370
Mech Ageing Dev. 2012 May;133(5):215-25
pubmed: 22738657
PLoS One. 2008 Apr 30;3(4):e2063
pubmed: 18446241
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
pubmed: 12184808
Biochem Biophys Res Commun. 2006 Feb 10;340(2):544-52
pubmed: 16376857
PLoS One. 2012;7(5):e37004
pubmed: 22623968
Stem Cell Res Ther. 2017 Nov 2;8(1):247
pubmed: 29096714
Sci Rep. 2017 Apr 27;7:46731
pubmed: 28447618
Anticancer Res. 2000 Jul-Aug;20(4):2485-7
pubmed: 10953315
BMC Cell Biol. 2010 May 08;11:32
pubmed: 20459680
Methods Mol Biol. 2012;879:403-42
pubmed: 22610574
Sci Rep. 2018 Sep 21;8(1):14193
pubmed: 30242278
Ann N Y Acad Sci. 1998 Apr 15;842:132-7
pubmed: 9599303
J Dent Res. 2011 Mar;90(3):341-6
pubmed: 21297017
HNO. 2010 Jun;58(6):556-63
pubmed: 20464362
Oral Dis. 2008 Jan;14(1):15-24
pubmed: 18173444
PLoS One. 2008 May 21;3(5):e2213
pubmed: 18493317
Hepatology. 2003 Jul;38(1):104-13
pubmed: 12829992
Sci Rep. 2015 Jun 09;5:10106
pubmed: 26054627
Eur J Cell Biol. 2009 Jul;88(7):409-21
pubmed: 19410331
PLoS One. 2012;7(8):e43255
pubmed: 22905242
Cytotherapy. 2012 Apr;14(4):401-11
pubmed: 22149184
J Mol Histol. 2017 Dec;48(5-6):329-336
pubmed: 28766180
Development. 2018 Nov 5;145(21):
pubmed: 30305288
Int J Oral Sci. 2022 Oct 10;14(1):49
pubmed: 36216809
Sci Transl Med. 2015 Sep 16;7(305):305ra147
pubmed: 26378247
Stem Cell Res Ther. 2017 Apr 26;8(1):102
pubmed: 28446235
J Contemp Dent Pract. 2019 Aug 1;20(8):978-986
pubmed: 31797858
Sci Rep. 2017 Oct 5;7(1):12707
pubmed: 28983091
Crit Rev Oral Biol Med. 2003;14(3):213-25
pubmed: 12799324
Stem Cells Dev. 2008 Jun;17(3):509-18
pubmed: 18522496
Clin Oral Investig. 2014 Apr;18(3):847-56
pubmed: 23900792
Oral Dis. 2011 Mar;17(2):143-53
pubmed: 20796229
ALTEX. 2018;35(1):99-118
pubmed: 28800376
Radiother Oncol. 2009 Sep;92(3):466-71
pubmed: 19625095
PLoS One. 2012;7(11):e48945
pubmed: 23155430
J Mol Histol. 2018 Feb;49(1):1-15
pubmed: 29181608
Stem Cells Transl Med. 2012 Nov;1(11):771-82
pubmed: 23197689
Nat Commun. 2018 Oct 11;9(1):4216
pubmed: 30310071
Tissue Eng Part A. 2010 Mar;16(3):983-93
pubmed: 19839721
In Vitro Cell Dev Biol Anim. 2020 Jan;56(1):85-95
pubmed: 31768763